Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
21 participants
INTERVENTIONAL
2025-11-17
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Plant Based High Energy High Protein Oral Nutritional Supplement on Nutritional Intake in Patients With or at Risk of Disease Related Malnutrition.
NCT06781619
Improving the Anabolic Action of Plant-based Foods Using Complementary Proteins
NCT06781723
Whole Body Protein Metabolism of a Whey/EAA Supplement Using Continuous Oral Stable Isotopes
NCT04612400
Amino Acid Concentrations in Serum After Intake of Different Protein Sources
NCT06153225
Protein Supplementation and Endurance Exercise Adaptations
NCT03462381
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High Dose Extended Release Protein
Extended release nutritional protein
Participants will consume a beverage with extended release protein.
Negative Dose Extended Release Protein
Negative Dose
Participants will consume a beverage with 15g less extended release protein than either the low dose cohort or the high dose cohort.
Control
Control
Participants will consume a beverage with standard nutritional protein.
Low Dose Extended Release Protein
Extended release nutritional protein
Participants will consume a beverage with extended release protein.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Extended release nutritional protein
Participants will consume a beverage with extended release protein.
Control
Participants will consume a beverage with standard nutritional protein.
Negative Dose
Participants will consume a beverage with 15g less extended release protein than either the low dose cohort or the high dose cohort.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body mass index (BMI) of 20 - 28 kg/m2, inclusive.
3. Non-user of tobacco or nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 12 months of Visit 1, with no plans to begin use during the study period.
4. Score of 7 to 10 on the Vein Access Scale at Visit 1.
5. No health conditions that would prevent him/her from fulfilling the study requirements as judged by the Clinical Investigator on the basis of medical history.
6. Willing to adhere to all study procedures, including lifestyle considerations (see section 6.3), and sign forms providing informed consent to participate in the study and authorization to release relevant protected health information to the Clinical Investigator.
Exclusion Criteria
1. Currently in a habitual exercise training program (≥ 3 d/wk of structured exercise) or plans to initiate an exercise training program during the study period.
2. Uncontrolled hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg) as defined by the blood pressure measured at visit 1. Stable use of hypertension medication is allowed (defined as no change in medication regimen ≤ 90 d of visit 1).
3. History or presence of clinically important cardiac, renal, hepatic, endocrine, pulmonary, biliary, pancreatic, or neurological disorders that may affect the participant's ability to adhere to the study protocol and/or affect study outcomes, in the judgment of the Investigator.
4. Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period.
5. Any signs or symptoms of active infection of clinical relevance (e.g., urinary tract or respiratory) within 5 days prior to any test visit. If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have resolved and any treatment has been completed at least 5 d prior to testing.
6. History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
7. History of any major trauma or major surgical event within 2 months of visit 1.
8. History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional.
Exclusionary products related criteria
9. Recent history of (within 12 months of screening; visit 1) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as \>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).
10. Recent use of anti-hyperglycemic (e.g., metformin, insulin, DPP 4 inhibitors, SGLT-2 inhibitors, GIP agonist, Pioglitazone, or Sulfonylureas) or GLP-1 analogue (e.g., Ozempic or Wegovy semaglutide, Mounjaro trizapatide) prescription medications within 6 mo of visit 1.
11. Unstable use of any prescription medication, where stable use is defined as no change in dose or medication type within 90 d of visit 1.
12. Exposed to any non-registered drug product within 30 d of visit 1.
13. Antibiotic use within 30 d of visit 1 and throughout the study period.
14. Steroid use within 30 d of visit 1 and throughout the study period.
15. Current habitual user (≥ 3 days/week ≤ 30 d of visit 1) of anti-inflammatory medications (e.g., NSAIDs, acetaminophen, etc.).
16. Habitual users (i.e., daily or almost daily) of marijuana and hemp products, including CBD products. Occasional use (e.g., couple times a month) within 12 months of visit 1 is allowed but requires at least a 14 d washout prior to visit 1 and the participant must be willing to refrain from use during the study (sleep aids and topical lotions/creams are allowed).
General safety related criteria
17. Known allergy or sensitivity to any ingredients or potential allergens contained in the study product or standard meals.
18. Self-report of blood donation totaling between 101-449 mL of blood within 30 d prior to visit 1 or a blood donation of ≥450 mL within 56 days prior to visit 1, or plasma donations within 48 h of visit 1. As well as any plans to donate blood or plasma during the study period.
19. Any condition the Investigator believes would interfere with the participant's ability to provide informed consent or comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United States Department of Defense (DOD)
UNKNOWN
VitaKey Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Biofortis
Addison, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLP0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.